Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma

NCT06829771 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Large B Cell Lymphoma

Interventions

DRUG: TQB2825 injection +R-CHOP regimen
DRUG: TQB2825 injection + GemOx

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.